Literature DB >> 35398344

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.

Laura D Wood1, Marcia Irene Canto2, Elizabeth M Jaffee3, Diane M Simeone4.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our understanding of the biology of PDAC have revealed new opportunities for early detection and targeted therapy of PDAC. In this review, we discuss the pathogenesis of PDAC, including molecular alterations in tumor cells, cellular alterations in the tumor microenvironment, and population-level risk factors. We review the current status of surveillance and early detection of PDAC, including populations at high risk and screening approaches. We outline the diagnostic approach to PDAC and highlight key treatment considerations, including how therapeutic approaches change with disease stage and targetable subtypes of PDAC. Recent years have seen significant improvements in our approaches to detect and treat PDAC, but large-scale, coordinated efforts will be needed to maximize the clinical impact for patients and improve overall survival.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Cancer Screening; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma

Mesh:

Year:  2022        PMID: 35398344      PMCID: PMC9516440          DOI: 10.1053/j.gastro.2022.03.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  169 in total

Review 1.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

2.  Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis.

Authors:  Juan E Corral; Ananya Das; Marco J Bruno; Michael B Wallace
Journal:  Pancreas       Date:  2019-04       Impact factor: 3.327

3.  Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

Authors:  Jay B Fell; John P Fischer; Brian R Baer; James F Blake; Karyn Bouhana; David M Briere; Karin D Brown; Laurence E Burgess; Aaron C Burns; Michael R Burkard; Harrah Chiang; Mark J Chicarelli; Adam W Cook; John J Gaudino; Jill Hallin; Lauren Hanson; Dylan P Hartley; Erik J Hicken; Gary P Hingorani; Ronald J Hinklin; Macedonio J Mejia; Peter Olson; Jennifer N Otten; Susan P Rhodes; Martha E Rodriguez; Pavel Savechenkov; Darin J Smith; Niranjan Sudhakar; Francis X Sullivan; Tony P Tang; Guy P Vigers; Lance Wollenberg; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2020-04-06       Impact factor: 7.446

4.  Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Norihiro Sato; Takashi Ueki; Noriyoshi Fukushima; Christine A Iacobuzio-Donahue; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

5.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

6.  Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model in a Diverse and Integrated Healthcare Setting.

Authors:  Wansu Chen; Rebecca K Butler; Eva Lustigova; Suresh T Chari; Bechien U Wu
Journal:  Dig Dis Sci       Date:  2020-02-28       Impact factor: 3.199

7.  Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.

Authors:  Yuko Omori; Yusuke Ono; Mishie Tanino; Hidenori Karasaki; Hiroshi Yamaguchi; Toru Furukawa; Katsuro Enomoto; Jun Ueda; Atsuko Sumi; Jin Katayama; Miho Muraki; Kenzui Taniue; Kuniyuki Takahashi; Yoshiyasu Ambo; Toshiya Shinohara; Hiroshi Nishihara; Junpei Sasajima; Hiroyuki Maguchi; Yusuke Mizukami; Toshikatsu Okumura; Shinya Tanaka
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

8.  Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series.

Authors:  Vinciane Rebours; Marie-Christine Boutron-Ruault; Matthieu Schnee; Claude Férec; Frédérique Maire; Pascal Hammel; Philippe Ruszniewski; Philippe Lévy
Journal:  Am J Gastroenterol       Date:  2008-01       Impact factor: 10.864

9.  Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer.

Authors:  Robert S Banh; Douglas E Biancur; Keisuke Yamamoto; Albert S W Sohn; Beth Walters; Miljan Kuljanin; Ajami Gikandi; Huamin Wang; Joseph D Mancias; Robert J Schneider; Michael E Pacold; Alec C Kimmelman
Journal:  Cell       Date:  2020-11-02       Impact factor: 41.582

10.  Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.

Authors:  Ana De Jesus-Acosta; Elizabeth A Sugar; Peter J O'Dwyer; Ramesh K Ramanathan; Daniel D Von Hoff; Zeshaan Rasheed; Lei Zheng; Asma Begum; Robert Anders; Anirban Maitra; Florencia McAllister; N V Rajeshkumar; Shinichi Yabuuchi; Roeland F de Wilde; Bhavina Batukbhai; Ismet Sahin; Daniel A Laheru
Journal:  Br J Cancer       Date:  2019-12-20       Impact factor: 7.640

View more
  2 in total

Review 1.  Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.

Authors:  Ruichao Li; Guangbing Xiong; Jun Zhao; Lin Yang
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF-κB Signaling Pathway.

Authors:  So Eun Youn; Fen Jiang; Hye Yun Won; Da Eun Hong; Tae Heung Kang; Yun-Yong Park; Sang Seok Koh
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.